Gilead pencils in potential buyout of Pionyr Immunotherapeutics
.jpg)
Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.
Gilead Sciences has agreed to pay $275 million for a 49.9% share in Pionyr Immunotherapeutics, a privately held company developing first-in-class cancer immunotherapies, with the exclusive option to purchase the remainder of Pionyr.
Whether or not Gilead chooses to buy the remaining shares may well rest upon the outcomes of the Phase Ib studies for PY314 and PY159. If they decide to go ahead, the remaining shares will cost then a further $315 million and up to $1.15 billion in potential future milestone payments.
In addition, Gilead will provide Pionyr with additional funding for the PY314 and PY159 clinical programs, as well as ongoing R&D programs.
Pionyr’s Myeloid Tuning therapies have the potential to treat patients who currently do not benefit from checkpoint inhibitor therapies. PY314 and PY159 have demonstrated preclinical efficacy, suggesting potential in solid tumors in combination with established anti-PD(L)-1 agents. Pionyr plans to file investigational new drug (IND) applications with the FDA for both PY314 and PY159 in the third quarter of this year.
“This agreement underscores the value of our myeloid tuning platform and the potential of our pipeline of antibody therapeutics designed to turbocharge the immune system within the tumor microenvironment,” said Steven P. James, President and CEO, Pionyr.
“PY314 and PY159 are first-in-class antibodies designed to remove or reprogram, respectively, the immune suppressive cells in the tumor microenvironment and thereby enhance anti-tumor immunity. We are grateful that Gilead has acknowledged the promise of this transformational approach to potentially benefit patients across a range of solid tumors.”
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine -
News Investors turn attention to biotechs with clear path to market
Companies that are further down the road to market are more attractive to investors than those in early development -
News Tonix strives for pandemic readiness with new US manufacturing facility
The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance